Canada-based Response Biomedical has expanded the scope of its agreement with China-based Shanghai Elite Biotech to distribute its cardiovascular portfolio of RAMP products.
8 February 2015
3 November 2014
US-based medical device firm Cardiovascular Systems (CSI) has received CE Mark for its Stealth 360º Orbital Atherectomy System (OAS), which is indicated to treat patients who suffer from peripheral arterial...
12 June 2014
US-based Cardiovascular Systems (CSI) has started enrolling patients in its coronary orbital atherectomy system trial (COAST), designed to evaluate safety and efficacy, as well as economic outcomes, of CSI’s new...
11 March 2014
Cardiovascular Systems has obtained US Food and Drug Administration (FDA) clearance for a new size of its Diamondback 360 peripheral orbital atherectomy system (OAS), designed for treating peripheral arterial disease...
23 October 2013
US-based Cardiovascular Systems has received pre-market approval (PMA) from the US Food and Drug Administration (FDA) to market its Diamondback 360 coronary orbital atherectomy system (OAS), designed to treat severely...
26 August 2013
Allied Healthcare Group has obtained Conformité Européenne (CE) marking for its lead regenerative product CardioCel, used for congenital heart disease treatment and cardiovascular repair.
7 August 2013
CorMatrix Cardiovascular has received three patents in the US for its replacement heart valves that use a biomaterial called extracellular matrix (ECM).
29 April 2013
Diagnostic firm LipoScience, in partnership with Cleveland Clinic, has commenced the clinical development phase of a diagnostic test for cardiovascular disease based upon the gut flora metabolite trimethylamine-N-oxide (TMAO).
22 January 2013
CorMatrix Cardiovascular has completed a trial of its CorMatrix ECM technology and confirmed safety of its usage to close the pericardium of patients undergoing postoperative coronary artery bypass grafting (CABG).
11 December 2012
The European Union has granted CE mark approval to BG Medicine's diagnostic blood assay, designed to identify individuals at high-risk for near-term major cardiovascular events including heart attack and stroke.